BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26993268)

  • 1. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.
    Manchanda R; Burnell M; Loggenberg K; Desai R; Wardle J; Sanderson SC; Gessler S; Side L; Balogun N; Kumar A; Dorkins H; Wallis Y; Chapman C; Tomlinson I; Taylor R; Jacobs C; Legood R; Raikou M; McGuire A; Beller U; Menon U; Jacobs I
    J Med Genet; 2016 Jul; 53(7):472-80. PubMed ID: 26993268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
    Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
    BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
    Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Pragmatic Testing-Eligibility Framework for Population Mutation Screening: The Example of
    Best AF; Tucker MA; Frone MN; Greene MH; Peters JA; Katki HA
    Cancer Epidemiol Biomarkers Prev; 2019 Feb; 28(2):293-302. PubMed ID: 30692095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
    Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
    Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
    Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
    Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.
    Burnell M; Gaba F; Sobocan M; Desai R; Sanderson S; Loggenberg K; Gessler S; Side L; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
    BJOG; 2022 Nov; 129(12):1970-1980. PubMed ID: 35781768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community attitudes towards a Jewish community BRCA1/2 testing program.
    Cousens N; Kaur R; Meiser B; Andrews L
    Fam Cancer; 2017 Jan; 16(1):17-28. PubMed ID: 27480161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced counselling for women undergoing BRCA1/2 testing: Impact on knowledge and psychological distress-results from a randomised clinical trial.
    Roussi P; Sherman KA; Miller S; Buzaglo J; Daly M; Taylor A; Ross E; Godwin A
    Psychol Health; 2010 Apr; 25(4):401-15. PubMed ID: 20204945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
    Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
    Nielsen SM; De Simone LM; Olopade OI
    J Genet Couns; 2018 Dec; 27(6):1405-1410. PubMed ID: 29946849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Log odds of carrying an Ancestral Mutation in BRCA1 or BRCA2 for a Defined personal and family history in an Ashkenazi Jewish woman (LAMBDA).
    Apicella C; Andrews L; Hodgson SV; Fisher SA; Lewis CM; Solomon E; Tucker K; Friedlander M; Bankier A; Southey MC; Venter DJ; Hopper JL
    Breast Cancer Res; 2003; 5(6):R206-16. PubMed ID: 14580256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.